Cheplapharm Benefits As Takeda Sheds More Older Products
$562m Deal Covers Mainly Canada, Europe
Japanese major presses on with post-Shire divestments even after passing strategic target.
You may also be interested in...
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
A choice asset in the middle of a pandemic, pharma companies could see the investment bubble burst once normalcy is on the horizon. But interest will continue in innovators, rather than big pharma specifically, predicts an expert panel featuring Biogen's chairman, a former Sanofi CEO and an ex-NIH director.
Danish firm picks up portfolio and manufacturing sites, along with around 600 employees.